Enfermedad de Parkinson

Volver al artículo.

Referencias para el artículo

  1. Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992;49:149–51.
  2. Carter JH, Nutt JG, Woodward WR, et al. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson’s disease. Neurology 1989;39:552–6.
  3. Pincus JH, Barry KM, Dietary method for reducing fluctuations in Parkinson’s disease. Yale J Biol Med 1987;60:133–7.
  4. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674–9.
  5. Kempster PA, Wahlqvist ML. Dietary factors in the management of Parkinson’s disease. Nutr Rev 1994;52:51–8 [review].
  6. Reuter I, Engelhardt M, Stecker K, Baas H. Therapeutic value of exercise training in Parkinson’s disease. Med Sci Sports Exerc 1999;31:1544–9.
  7. Corrigan FM, Wienburg CL, Shore RF, et al. Organochlorine insecticides in substantia nigra in Parkinson’s disease. J Toxicol Environ Health 2000;59:229–34.
  8. Fleming L, Mann JB, Bean J, et al. Parkinson’s disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100–3.
  9. Corrigan FM, Murray L, Wyatt CL, Shore RF. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson’s disease. Exp Neurol 1998;150:339–42.
  10. Ritz B, Yu F. Parkinson’s disease mortality and pesticide exposure in California 1984–1994. Int J Epidemiol 2000;29:323–9.
  11. Geusau A, Tschachler E, Meixner M, et al. Olestra increases faecal excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Lancet 1999;354:1266–7.
  12. Moser GA, McLachlan MS. A non-absorbable dietary fat substitute enhances elimination of persistent lipophilic contaminants in humans. Chemosphere 1999;39:1513–21.
  13. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541–50.)
  14. de Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 1997;54:762–5.
  15. Scheider WL, Hershey LA, Vena JE, et al. Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease. Mov Disord 1997;12:190–6.
  16. Molina JA, de Bustos F, Jimenez-Jimenez FJ, et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson’s disease. J Neural Transm 1997;104:1287–93.
  17. Federico A, Battisti C, Formichi P, Dotti MT. Plasma levels of vitamin E in Parkinson’s disease. J Neural Transm Suppl1995;267–70.
  18. Morens DM, Grandinetti A, Waslien CI, et al. Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology 1996;46:1270–4.
  19. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 1992;32:S128–32.
  20. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 1998;44:S160–6.
  21. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 1992;32:S128–32.
  22. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 1998;44:S160–6.
  23. Vatassery GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 1998;50:1900–2.
  24. Pappert EJ, Tangney CC, Goetz CG, et al. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson’s disease patients: dose-response study and correlations with plasma levels. Neurology 1996;47:1037–42.
  25. Baker AB. Treatment of paralysis agitans with vitamin B6. JAMA 1941;116:2484.
  26. Pfeiffer R, Ebadi M. On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients. J Neurochem 1972;19(9):2175–81.
  27. Leon AS, Spiegel HE, Thomas G, Abrams WB. Pyridoxine antagonism of levodopa in parkinsonism. JAMA 1971;218(13):1924–7.
  28. Mars H. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson’s disease. Trans Am Neurol Assoc 1973;98:241–5.
  29. Smythies JR, Halsey JH. Treatment of Parkinson’s disease with l-methionine. South Med J 1984;77:1577.
  30. Bender DA, Earl CJ, Lees AJ. Niacin depletion in Parkinsonian patients treated with L-dopa, benserizide and carbidopa. Clin Sci 1979;56:89–93.
  31. Cotzias GC, Lawrence WH, Papavasiliou PS, Duby SE. Nicotinamide ineffective in parkinsonism. N Engl J Med 1972;287:147.
  32. Birkmayer JGD, Vrecko C, Volc D, et al. Nicotinamide adenine dinucleotide (NAD). A new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Neurol Scand 1993;87(Suppl 146):32–5.
  33. Birkmayer JGD. Coenzyme nicotinamide adenine dinucleotide. New therapeutic approach to improving dementia of the Alzheimers type. Ann Clin Lab Sci 1996;26:1–9.
  34. Wright JV. Interview: Alzheimer’s, Parkinson’s, NADH research. Jorg Birkmayer, M.D. Nutr Healing 1997;May:5–6.
  35. Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson’s disease with NADH. Acta Neurologica Scand 1994;90:345–7.
  36. Mayeux R, Stern Y, Sano M, et al. The relationship of serotonin to depression in Parkinson’s disease. Mov Disord 1988;3:237–44.
  37. Bastard J, Truelle JL, Emile J. Effectiveness of 5 hydroxy-tryptophan in Parkinson’s disease. Presse Med 1976;5:1836–7.
  38. Sano VI, Taniguchi K. L-5-hydroxytryptophan (L-5-HTP) therapy in Parkinson’s disease. MMWR 1972;114:1717–9.
  39. Chase TN, Ng LK, Watanabe AM. Parkinson’s disease: modification by 5-hydroxytryptophan. Neurology 1972;22:479–84.
  40. Chase TN, Ng LK, Watanabe AM. Parkinson’s disease. Modification by 5-hydroxytryptophan. Neurology 1972;22:479–84.
  41. Mendlewicz J, Youdim MB. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord 1980;2:137–46.
  42. Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain, vol 7. New York: Raven Press, 1986.
  43. Lemoine P, Robelin N, Sebert P, Mouret J. L-tyrosine: a long term treatment of Parkinson’s disease. C R Acad Sci III 1989;309:43–7.
  44. Heller B, Fischer E, Martin R. Therapeutic action of D-phenylalanine in Parkinson’s disease. Arzneimittelforschung 1976;26:577–9.
  45. Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain, vol 7. New York: Raven Press, 1986.
  46. Riekkinen P, Rinne UK, Pelliniemi TT, Sonninen V. Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. Arch Neurol 1975;32:25–7.
  47. Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res 1989;317:1235–46.
  48. Gaby AR. Don’t believe everything you read. Townsend Letter for Doctors and Patients 1997;July:125–6.
  49. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 1997;49:1273–8.
  50. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology1997;49:1273–8.
  51. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1 a-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;66:64–8.
  52. Forsleff L, Schauss AG, Bier ID, et al. Evidence of functional zinc deficiency in Parkinson’s disease. J Altern Complement Med 1999;5:57–64.
  53. Uitti RJ, Rajput AH, Rozdilsky B, et al. Regional metal concentrations in Parkinson’s disease, other chronic neurological diseases, and control brains. Can J Neurol Sci 1989;16:310–4.
  54. Pall HS, Williams AC, Blake DR, et al. Raised cerebrospinal fluid copper concentration in Parkinson’s disease. Lancet 1987;2(8553):238–41.
  55. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953–75.
  56. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953–75.
  57. Pall HS, Williams AC, Blake DR, et al. Raised cerebrospinal fluid copper concentration in Parkinson’s disease. Lancet 1987;2(8553):238–41.
  58. An alternative medicine treatment for Parkinson’s disease: results of a multicenter clinical trial. HP-200 in Parkinson’s Disease Study Group. J Altern Complement Med 1995;1:249–55.
  59. Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord 1997;12:946–51.